Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 588,411 shares of AMLX stock, worth $9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

588,411

Previous 372,853 57.81%

Holding current value

$9 Million

Previous $1.32 Million 185.9%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$3.31 - $6.5 $713,496 - $1.4 Million	215,558 Added 57.81%	588,411 $3.77 Million
Q1 2025 Sep 15, 2025	SELL	$3.0 - $4.15 $646,674 - $894,565	-215,558 Reduced 36.63%	372,853 $1.32 Million
Q1 2025 May 09, 2025	BUY	$3.0 - $4.15 $221,712 - $306,701	73,904 Added 24.72%	372,853 $1.32 Million
Q4 2024 Feb 06, 2025	SELL	$2.94 - $7.03 $9,763 - $23,346	-3,321 Reduced 1.1%	298,949 $1.13 Million
Q3 2024 Nov 12, 2024	SELL	$1.65 - $3.24 $361,925 - $710,690	-219,349 Reduced 42.05%	302,270 $979,000
Q2 2024 Aug 12, 2024	BUY	$1.62 - $2.71 $138,859 - $232,290	85,716 Added 19.66%	521,619 $991,000
Q1 2024 May 08, 2024	BUY	$2.71 - $19.57 $130,846 - $944,898	48,283 Added 12.46%	435,903 $1.24 Million
Q4 2023 Feb 06, 2024	BUY	$12.07 - $18.46 $262,619 - $401,652	21,758 Added 5.95%	387,620 $5.71 Million
Q3 2023 Nov 08, 2023	BUY	$18.08 - $23.45 $730,070 - $946,911	40,380 Added 12.41%	365,862 $6.7 Million
Q2 2023 Aug 09, 2023	BUY	$20.98 - $31.42 $113,208 - $169,542	5,396 Added 1.69%	325,482 $7.02 Million
Q1 2023 May 11, 2023	BUY	$27.71 - $40.93 $65,589 - $96,881	2,367 Added 0.74%	320,086 $9.39 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $2.29 Million - $3.02 Million	76,980 Added 31.98%	317,719 $11.7 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $2.92 Million - $5.27 Million	170,330 Added 241.92%	240,739 $6.78 Million
Q2 2022 Aug 15, 2022	SELL	$6.85 - $19.93 $17,933 - $52,176	-2,618 Reduced 3.58%	70,409 $1.36 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $938,396 - $2.4 Million	73,027 New	73,027 $939,000

Others Institutions Holding AMLX

# of Institutions

148

Shares Held

75.8M

Call Options Held

212K

Put Options Held

40.6K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $895M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Transaction History